CELZ — Creative Medical Technology Hol

Is CELZ overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Creative Medical Technology Hol (CELZ) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.95. The rating moved from Strong Oversold to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

Creative Medical Technology Hol (CELZ) is a microcap healthcare/security with limited public disclosure and low liquidity, making it highly sensitive to market sentiment and financing needs. Near-term market context is risk-off, and sector-level headwinds (slowed device IPO activity and payer uncertainty) increase the chance of downward pressure absent a clear catalyst. Key vulnerabilities include potential dilution, reimbursement and regulatory execution risk, and competition; upside would require a material clinical, regulatory or partnership milestone. Given the information asymmetry and macro/sector backdrop, downside scenarios are more probable in the next 1–4 weeks unless new positive disclosures emerge.

Key factors

  • Microcap / low-liquidity profile increases volatility and makes shares sensitive to dilution or small flows
  • Macro risk-off market tone and recent defensive rotation into safety assets reduces demand for speculative healthcare/device names
  • Sector-wide headwinds: cooling IPO window for digital-health & devices dampens investor appetite for early-stage device-related firms
  • No EDGAR filing comparison available in the provided data, limiting transparency into recent financials, cash runway and operating performance
  • Medicare drug-price negotiation and payer reimbursement pressure increase commercial uncertainty for healthcare products that require broad coverage
  • Lack of social/research sentiment data increases information asymmetry and heightens reliance on sparse public catalysts
  • Potential binary outcomes: meaningful upside from a clinical/regulatory milestone or partnership, but binary events amplify downside on misses

Risks

  • Highly dilutive equity financings if cash runway is limited, which can sharply reduce per‑share value
  • Regulatory or clinical setbacks (if applicable to the company’s technology) can trigger steep price declines
  • Weak or unclear reimbursement pathway and payer resistance could constrain commercial adoption and revenue potential
  • Competitive pressure from larger medtech and pharma players, and broader innovation (including combo therapeutics) that could reduce addressable market
  • Market illiquidity: wide spreads and low volumes can cause large intraday moves unrelated to fundamentals
  • Adverse policy developments (e.g., Medicare negotiation outcomes) that reduce pricing leverage for healthcare products
  • Limited publicly available financial disclosures makes due diligence harder and increases investor uncertainty

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CELZ — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.